Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT01545947
Title Study Assessing Safety, Pharmacokinetics and Efficacy of CC-223 With Either Erlotinib or Oral Azacitidine in Advanced Non-Small Cell Lung Cancer
Recruitment Completed
Gender both
Phase Phase I
Variant Requirements No
Sponsors Celgene Corporation
Indications

lung non-small cell carcinoma

Therapies

Azacitidine + Onatasertib

Erlotinib + Onatasertib

Age Groups: adult
Covered Countries USA | ESP

Facility Status City State Zip Country Details
Cedars Sinai Medical Center, Inflammatory Bowel Disease Center Los Angeles California 90048 United States Details
University of California, San Francisco San Francisco California 9411 United States Details
NYU School of Medicine New York New York 10016 United States Details
Cancer Center of the Carolinas Greenville South Carolina 29605 United States Details
Henry-Joyce Cancer Clinic Nashville Tennessee 37232-5505 United States Details
Mary Crowley Cancer Research Centers - Medical City Dallas Texas 75201 United States Details
The University of Texas MD Anderson Cancer Center Houston Texas 77030 United States Details
Vall d´Hebron University Hospital Barcelona 08035 Spain Details
Hospital Virgen del Rocio Servicio de Hematologia Sevilla 41013 Spain Details
*Shaded cells indicate that there was no data available from clincialtrials.gov for the field